Finanza

Discussioni Tecnici Previsione Stagionalità

EBIT su Trevi Therapeutics, Inc..

Dati annuali

2018

2019

2020

2021

2022

2023

TTM

‪‪−52,00 M‬‬

‪‪−39,00 M‬‬

‪‪−26,00 M‬‬

‪‪−13,00 M‬‬

‪0,00‬

Periodo

Valore

Variazione

Variazione %

TTM

‪‪−48,22 M‬‬

‪‪−14,29 M‬‬

‪−42,13‬%

2023

‪‪−33,92 M‬‬

‪‪−3,98 M‬‬

‪−13,29‬%

2022

‪‪−29,94 M‬‬

+‪‪2,53 M‬‬

+‪7,80‬%

2021

‪‪−32,48 M‬‬

+‪‪13,00 K‬‬

+‪0,04‬%

2020

‪‪−32,49 M‬‬

‪‪−5,84 M‬‬

‪−21,93‬%

2019

‪‪−26,64 M‬‬

‪‪−8,24 M‬‬

‪−44,75‬%

2018

Dati trimestrali

Q2 '18

Q4 '18

Q1 '19

Q2 '19

Q3 '19

Q4 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

‪‪−16,00 M‬‬

‪‪−12,00 M‬‬

‪‪−8,00 M‬‬

‪‪−4,00 M‬‬

‪0,00‬

Periodo

Valore

Variazione

Variazione %

Q3 '24

‪‪−14,09 M‬‬

‪‪−798,00 K‬‬

‪−6,00‬%

Q2 '24

‪‪−13,29 M‬‬

‪‪−1,38 M‬‬

‪−11,62‬%

Q1 '24

‪‪−11,91 M‬‬

‪‪−2,97 M‬‬

‪−33,28‬%

Q4 '23

‪‪−8,93 M‬‬

+‪‪112,00 K‬‬

+‪1,24‬%

Q3 '23

‪‪−9,04 M‬‬

‪‪−663,00 K‬‬

‪−7,91‬%

Q2 '23

‪‪−8,38 M‬‬

‪‪−819,00 K‬‬

‪−10,83‬%

Q1 '23

‪‪−7,56 M‬‬

‪‪−906,00 K‬‬

‪−13,61‬%

Q4 '22

‪‪−6,66 M‬‬

+‪‪1,75 M‬‬

+‪20,80‬%

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21

Q4 '20

Q3 '20

Q2 '20

Q1 '20

Q4 '19

Q3 '19

Q2 '19

Q1 '19

Q4 '18

Q2 '18